Mind Medicine Mindmed Inc (MNMD)

$13.39 +0.44 (3.40%)
Market Cap 1.28B
Revenue (ttm) 0.00
Net Income (ttm) -108.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.31
Volume 1,109,600
Avg Vol 1,900,830
Day's Range N/A - N/A
Shares Out 98.51M
Stochastic %K 54%
Beta 2.57
Analysts Strong Sell
Price Target $28.58

Company Profile

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is head...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 220 6633
Address:
One World Trade Center, Suite 8500, New York, United States
kareem1988
kareem1988 Jan. 1 at 1:01 PM
2026 BIOTECH WATCHLIST These four biotechs have major clinical and regulatory catalysts in 2026. $DRTS (Alpha Tau Medical) The Play: Alpha DaRT for solid tumors. 2026 Catalyst: Japan PMDA approval decision expected early 2026. Why Watch: Transitioning to revenue. ASCO GI (Jan 15) is the next data dump. $MNMD (MindMed) The Play: MM120 for Anxiety (GAD) and Depression. 2026 Catalyst: Voyage Phase 3 data (H1) and Emerge data (mid-2026). $OCGN (Ocugen) The Play: Gene therapy for blindness (RP). 2026 Catalyst: Rolling BLA submission starts H1; Phase 3 liMeliGhT data in Q4. Why Watch: Gene-agnostic approach targeting a larger market than competitors. $SAVA (Cassava Sciences) The Play: Simufilam for TSC-related epilepsy. 2026 Catalyst: Pivot from Alzheimer’s to orphan disease.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 31 at 11:57 PM
Enter: $MNMD Calls Strike Price: $13 Expiry Date: FEB 20 2026 Buy in Price: $1.80 - $1.80 Sell Price: $3.74 Profit : +108% (Turn every $1 into $2.08) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Dec. 31 at 10:01 PM
$CMPS The More You Know ...... $ATAI $MNMD
0 · Reply
BullsVSBearsVSYoMomma
BullsVSBearsVSYoMomma Dec. 31 at 6:49 AM
$MNMD Gap up that needs to fill and back test before making the next move
0 · Reply
Rocketzz
Rocketzz Dec. 30 at 6:55 PM
$MNMD that was your dip. See you all at $20 next month
1 · Reply
daleloyd
daleloyd Dec. 30 at 4:15 PM
$MNMD I am looking forward to 2026 when I think this will begin to be a strong stock!Happy New Year, All!🥂
0 · Reply
BobbyCucumber
BobbyCucumber Dec. 30 at 3:37 AM
$MNMD ...$12-$14 consolidation would be great for a bit, looking good!
0 · Reply
minegolia
minegolia Dec. 29 at 8:32 PM
$MNMD 2026 will be the year for psychedelics companies. Favorable year overall, more people becoming aware of the benefits, and better legal landscape. 💎🔥
0 · Reply
MichaelNaussCMT
MichaelNaussCMT Dec. 29 at 5:28 PM
Very positive price action holding that $13 we broke from very well. $MNMD
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 29 at 5:28 PM
Enter: $MNMD Calls Strike Price: $14 Expiry Date: FEB 20 2026 Buy in Price: $1.50 - $1.60 Sell Price: $2.19 Profit : +46% (Turn every $1 into $1.46) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Latest News on MNMD
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 7:01 AM EST - 14 days ago

MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference

MindMed Announces New Employee Inducement Grant

Dec 15, 2025, 4:01 PM EST - 16 days ago

MindMed Announces New Employee Inducement Grant

MindMed Announces New Employee Inducement Grants

Dec 1, 2025, 4:01 PM EST - 4 weeks ago

MindMed Announces New Employee Inducement Grants

Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 9:46 PM EST - 7 weeks ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript

MindMed Reports Q3 2025 Financial Results and Business Updates

Nov 6, 2025, 4:01 PM EST - 7 weeks ago

MindMed Reports Q3 2025 Financial Results and Business Updates

MindMed to Participate in Upcoming Investor Conferences

Nov 5, 2025, 7:01 AM EST - 2 months ago

MindMed to Participate in Upcoming Investor Conferences

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Nov 3, 2025, 7:01 AM EST - 2 months ago

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Oct 30, 2025, 4:01 PM EDT - 2 months ago

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Oct 29, 2025, 10:14 PM EDT - 2 months ago

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Oct 29, 2025, 4:01 PM EDT - 2 months ago

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy

Oct 14, 2025, 12:28 PM EDT - 2 months ago

MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Oct 13, 2025, 2:54 PM EDT - 2 months ago

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Sep 19, 2025, 7:00 AM EDT - 3 months ago

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

Sep 4, 2025, 11:05 AM EDT - 4 months ago

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

MindMed to Participate in September Investor Conferences

Aug 28, 2025, 7:00 AM EDT - 4 months ago

MindMed to Participate in September Investor Conferences

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 9:48 PM EDT - 5 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

MindMed Reports Q2 2025 Financial Results and Business Updates

Jul 31, 2025, 4:01 PM EDT - 5 months ago

MindMed Reports Q2 2025 Financial Results and Business Updates

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

Jul 24, 2025, 7:00 AM EDT - 5 months ago

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

MindMed to Participate in June Investor Conferences

May 28, 2025, 7:00 AM EDT - 7 months ago

MindMed to Participate in June Investor Conferences

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 27, 2025, 7:00 AM EDT - 7 months ago

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 13, 2025, 7:00 AM EDT - 8 months ago

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

May 8, 2025, 9:55 AM EDT - 8 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

May 8, 2025, 7:00 AM EDT - 8 months ago

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 24, 2025, 7:00 AM EDT - 9 months ago

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Apr 15, 2025, 7:00 AM EDT - 9 months ago

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mar 17, 2025, 7:00 AM EDT - 10 months ago

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 12:10 PM EST - 10 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Mar 6, 2025, 7:00 AM EST - 10 months ago

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

MindMed to Present at Leerink's Global Healthcare Conference 2025

Mar 4, 2025, 7:00 AM EST - 10 months ago

MindMed to Present at Leerink's Global Healthcare Conference 2025

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 20, 2025, 7:00 AM EST - 11 months ago

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:00 AM EST - 11 months ago

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Jan 30, 2025, 7:00 AM EST - 1 year ago

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

MindMed to Be Added to the Nasdaq Biotechnology Index

Dec 19, 2024, 7:00 AM EST - 1 year ago

MindMed to Be Added to the Nasdaq Biotechnology Index

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Dec 16, 2024, 7:00 AM EST - 1 year ago

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

Dec 11, 2024, 7:00 AM EST - 1 year ago

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

Dec 5, 2024, 7:00 AM EST - 1 year ago

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

Dec 3, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Nov 18, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Mind Medicine: No News = Good News

Nov 10, 2024, 9:55 AM EST - 1 year ago

Mind Medicine: No News = Good News

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 8:06 PM EST - 1 year ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Nov 7, 2024, 4:01 PM EST - 1 year ago

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

Nov 4, 2024, 4:04 PM EST - 1 year ago

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

Oct 24, 2024, 7:00 AM EDT - 1 year ago

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

Psychedelic Stocks: Focus On Their Cash

Aug 15, 2024, 12:30 PM EDT - 1 year ago

Psychedelic Stocks: Focus On Their Cash

CMPS

Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 11:21 AM EDT - 1 year ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript

MindMed readying Phase III trials for LSD therapy to treat anxiety

Aug 13, 2024, 7:44 AM EDT - 1 year ago

MindMed readying Phase III trials for LSD therapy to treat anxiety

Pacific Defense Announces US Army CMFF Program Team

Aug 13, 2024, 7:01 AM EDT - 1 year ago

Pacific Defense Announces US Army CMFF Program Team

MRNS

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

Aug 13, 2024, 7:00 AM EDT - 1 year ago

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates

Aug 12, 2024, 12:47 PM EDT - 1 year ago

FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

Aug 12, 2024, 12:12 PM EDT - 1 year ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

ATAI CMPS CYBN

kareem1988
kareem1988 Jan. 1 at 1:01 PM
2026 BIOTECH WATCHLIST These four biotechs have major clinical and regulatory catalysts in 2026. $DRTS (Alpha Tau Medical) The Play: Alpha DaRT for solid tumors. 2026 Catalyst: Japan PMDA approval decision expected early 2026. Why Watch: Transitioning to revenue. ASCO GI (Jan 15) is the next data dump. $MNMD (MindMed) The Play: MM120 for Anxiety (GAD) and Depression. 2026 Catalyst: Voyage Phase 3 data (H1) and Emerge data (mid-2026). $OCGN (Ocugen) The Play: Gene therapy for blindness (RP). 2026 Catalyst: Rolling BLA submission starts H1; Phase 3 liMeliGhT data in Q4. Why Watch: Gene-agnostic approach targeting a larger market than competitors. $SAVA (Cassava Sciences) The Play: Simufilam for TSC-related epilepsy. 2026 Catalyst: Pivot from Alzheimer’s to orphan disease.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 31 at 11:57 PM
Enter: $MNMD Calls Strike Price: $13 Expiry Date: FEB 20 2026 Buy in Price: $1.80 - $1.80 Sell Price: $3.74 Profit : +108% (Turn every $1 into $2.08) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
macrossluvsrobotech
macrossluvsrobotech Dec. 31 at 10:01 PM
$CMPS The More You Know ...... $ATAI $MNMD
0 · Reply
BullsVSBearsVSYoMomma
BullsVSBearsVSYoMomma Dec. 31 at 6:49 AM
$MNMD Gap up that needs to fill and back test before making the next move
0 · Reply
Rocketzz
Rocketzz Dec. 30 at 6:55 PM
$MNMD that was your dip. See you all at $20 next month
1 · Reply
daleloyd
daleloyd Dec. 30 at 4:15 PM
$MNMD I am looking forward to 2026 when I think this will begin to be a strong stock!Happy New Year, All!🥂
0 · Reply
BobbyCucumber
BobbyCucumber Dec. 30 at 3:37 AM
$MNMD ...$12-$14 consolidation would be great for a bit, looking good!
0 · Reply
minegolia
minegolia Dec. 29 at 8:32 PM
$MNMD 2026 will be the year for psychedelics companies. Favorable year overall, more people becoming aware of the benefits, and better legal landscape. 💎🔥
0 · Reply
MichaelNaussCMT
MichaelNaussCMT Dec. 29 at 5:28 PM
Very positive price action holding that $13 we broke from very well. $MNMD
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 29 at 5:28 PM
Enter: $MNMD Calls Strike Price: $14 Expiry Date: FEB 20 2026 Buy in Price: $1.50 - $1.60 Sell Price: $2.19 Profit : +46% (Turn every $1 into $1.46) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
goral17
goral17 Dec. 29 at 5:23 PM
$MNMD When do we retest $2? Lol I heard my local vape shop is considering a buyout!
1 · Reply
ZacksResearch
ZacksResearch Dec. 29 at 5:14 PM
$MNMD just doubled in 6 months — and 2026 could be the real catalyst 👀🚀 MNMD is up 101% over the past six months as MM120 advances in phase III for GAD and MDD, with pivotal readouts slated for 2026 — a clear reason momentum investors are paying attention. See what’s in store for 2026 and why it matters 👉 https://www.zacks.com/stock/news/2809772/mnmd-stock-up-more-than-100-in-6-months-whats-in-store-for-2026?cid=sm-stocktwits-2-2809772-teaser-26615&ADID=SYND_STOCKTWITS_TWEET_2_2809772_TEASER_26615
0 · Reply
ZacksResearch
ZacksResearch Dec. 29 at 4:14 PM
$MNMD's 2026 pipeline: Make or break for Mind Medicine? 🚀 MindMed's lead candidate, MM120, is in phase III trials for GAD & MDD, with top-line data from Voyage expected in H1 2026 and Panorama in H2 2026. The stock surged 101.2% in six months, boosted by rapid pipeline progress, $258.9M financing, and outperforming the industry increase of 27.6%. Discover the potential catalysts for MNMD here 👉 https://www.zacks.com/stock/news/2809772/mnmd-stock-up-more-than-100-in-6-months-whats-in-store-for-2026?cid=sm-stocktwits-2-2809772-body-26616&ADID=SYND_STOCKTWITS_TWEET_2_2809772_BODY_26616
0 · Reply
ocho2point0
ocho2point0 Dec. 29 at 2:50 PM
$QNCCF news incoming around 10:30 - load now $MNMD $KSCP lookong strong $XRP.X
0 · Reply
ocho2point0
ocho2point0 Dec. 29 at 2:49 PM
$KSCP going to 4.74 $QNCCF $MNMD $XRP
0 · Reply
LibertarianTreehugger
LibertarianTreehugger Dec. 28 at 8:11 PM
Biohaven Falls Short in Depression Trial, Could Psychedelics be the Solution? https://jlsfund.substack.com/p/biohaven-falls-short-in-depression $BHVN $MNMD $COMP $ATAI
1 · Reply
a_rational_investor
a_rational_investor Dec. 27 at 5:46 PM
$MNMD really optimistic for the future. And the sector as a whole
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 27 at 5:24 PM
Enter: $MNMD Calls Strike Price: $13 Expiry Date: JAN 16 2026 Buy in Price: $1.35 - $1.42 Sell Price: $2.61 Profit : +93% (Turn every $1 into $1.93) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 26 at 7:53 PM
$MNMD RSI: 57.68, MACD: 0.3442 Vol: 0.53, MA20: 12.62, MA50: 12.33 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PnLView_1666
PnLView_1666 Dec. 26 at 3:13 PM
$MNMD biotech sentiment driven tight range watch volume
0 · Reply
TestimonialTitan
TestimonialTitan Dec. 26 at 12:40 PM
$MNMD Expectations are recalibrating toward pragmatic delivery instead of lofty projections. Efficiency initiatives must translate into measurable productivity. Demonstrated durability would lengthen investor time horizons. Sentiment should follow consistency rather than noise.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 26 at 2:50 AM
Enter: $MNMD Calls Strike Price: $14 Expiry Date: JAN 16 2026 Buy in Price: $0.92 - $1.05 Sell Price: $1.62 Profit : +76% (Turn every $1 into $1.76) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply